Type 1 diabetes mellitus treatment in seniors

Czech version

Authors: D. Janíčková Žďárská
Published in: Geriatrie a Gerontologie 2017, 6, č. 4: 163-167
Category: Review Article

Overview

Older adults with type 1 diabetes are at an elevated risk of severe hypoglycaemia and may have serious comorbid conditions. Problems with cognition, mobility, dexterity, vision, hearing, chronic pain, unpredictable eating and frailty interfere with the ability to follow complex insulin regimens. For the treatment of type 1 diabetes mellitus intensive insulin regime is the preferred choice with adequate frequent self-monitoring; we do not hesitate to use insulin analogues. Targets of metabolic compensation are individual, treatment regimens must be modified with the goal of minimizing hypoglycaemia and severe hyperglycaemia and maximizing quality of life.

Keywords:
type 1 diabetes mellitus – geriatric patient – insulin analogues – hypoglycaemia

Sources

1. Diamond Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. Diabet Med 2006; 23: 857–866.

2. Patterson CC, Dahlquist GG, Gyürüs E, et al. EURODIAB study group: Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–2020: a multicentre prospective registration study. Lancet 2009; 373: 2027–2033.

3. International Diabetes Federation. Diabetes Atlas. Brussels, International Diabetes Federation 2011.

4. Schutt M, Fach EM, Seufert J, et al. DPV Initiative and the German BMBF Competence Network Diabetes Network: Multiple complications and frequent severe hypoglycaemia in ‘elderly’ and ‘old’ patients with type 1 diabetes. Diabet Med 2012; 29: 176–179.

5. JDRF Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the JDRF Continuous Glucose Monitoring trial. Diabetes Care 2010; 33: 17–22.

6. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238–245.

7. Microvascular and acute complications in IDDM patiens: the EURODIAB IDDM Complications study. Diabetologia 1994; 37: 278–285.

8. Braak EW, Appelman AM, van de Laak M, et al. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000; 23: 1467–1471.

9. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35: 1897–1901.

10. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552–1561.

11. Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab 2009; 297: 194–201.

12. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29: 494–511.

13. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycaemia. Diabetes Care 1994; 17: 697–703.

14. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135–141.

15. Brierley EJ, Broughton DL, James OF, Alberti KG. Reduced awareness of hypoglycaemia in the elderly despite an intact counterregulatory response. Q J Med 1995; 88: 439–445.

16. Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513–1517.

17. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2010; 39: 641–654.

18. Centers for Disease Control and Prevention. Vision health initiative. Dostupné na: www.cdc.gov. 6 July 2013

19. Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med 2008; 149: 1–10.

20. Bainbridge KE, Hoffman HJ, Cowie CC. Risk factors for hearing impairment among U. S. adults with diabetes: National Health and Nutrition Examination Survey 1999–2004. Diabetes Care 2011; 34: 1540–1545.

21. Jaroslav Rybka. Zvláštnosti terapie diabetu u seniorů. Interní Med 2012; 14(8 a 9): 303–308.

22. Dhaliwal R, Weinstock RS. Management of type 1 diabetes in older adults. Diabetes Spectr 2014; 27(1): 9–20.

23. Pelikánová T, Bartoš V a kol. Praktická diabetologie. Maxdorf 2010.

24. Pena A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev 2016; 5(1): 69–75.

25. Haluzík M. Inzulin glargin 300 U/ml. Farmakoterapie 2015; 4: 474–479.

26. Adamíková A. Klinický význam bazálních inzulinů se zaměřením na Toujeo 300 U/ml. Vnitr Lek 2015; 61(11): 985–988.

27. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care [published online June 17, 2015].

28. Becker RHA, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab 2015; 17(3): 261–267.

29. Dailey G, Lavernia F. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Diabetes Obes Metab 2015;

30. Rosenstock J, et al. Basal insulin glargine (HOE 901) versus NPH insulin patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23(8): 1137–1142.

31. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U. S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23(5): 639–643.

32. DCCT (Diabetes Control and Complication Trial). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14).

33. Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes Metab Res Rev 2014; 30:104–119.

34. Janíčková Žďárská D, Piťhová P, Kvapil M. Možnosti terapie inzulinem v roce 2015. Klin Farmakol Farm 2015; 29(1): 30–34.

Labels

Geriatrics General practitioner for adults Orthopaedic prosthetics

Occurrence and development of depression at various types of facilities for seniors – use of Geriatric depression scale

Prevention of atheroslerotic cardiovascular events in frail patiens

Gastrointestinal bleeding – a significant risk for geriatric patients

COPD – news in diagnostics and treatment

Securing vascular access in geriatric patients

A frail patient with kidney failure

Repeated cardiopulmonary resuscitation of a geriatric patient – how did it go afterwards?

Article was published in

Geriatrics and Gerontology

2017 Issue 4